Skip to content

MAZE MAZE Total Current Liabilities

Total Current Liabilities at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$3.88B+2.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
$78.17M+635%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$40.81M-8.7%
Olema Pharmaceuticals, Inc. logo
Olema Pharmaceuticals, Inc.OLMA
$47.17M+81.0%
Zymeworks logo
ZymeworksZYME
$35.65M-45.2%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
$92.2M+2.5%

Other financials

Income statement

See full
Revenue$20.0M
Operating income-$26.6M+25.0%
Net income-$24.2M+26.2%
EPS (diluted)-$0.45+60.9%

Balance sheet

See full
Cash & equivalents$198.8M-32.5%
Total debt$61.2M+137%
Total equity$341.7M+17.0%
Total assets$419.7M+26.1%

Cash flow

See full
Operating cash flow-$39.1M-32.5%
CapEx$93.0K-68.9%
Free cash flow-$39.2M-31.5%

Valuation

See full
Market cap$1.48B+201%
Enterprise value$1.34B
P/S7.9×

Profitability

See full
Operating margin-71.5%
Net margin-65.4%
FCF margin-65.1%

Returns & leverage

See full
Return on equity-38.7%
Debt / equity0.2×+0.1×
Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MAZE's total current liabilities?
MAZE (MAZE) reported total current liabilities of $21.24M in Q1 2026.
How has MAZE's total current liabilities changed year-over-year?
MAZE's total current liabilities increased by 14.1% year-over-year, from $18.62M to $21.24M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.